Announcement on Obtaining the "Drug Registration Certificate" for Terbutaline Sulphate Solution for Nebulization
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining the "Drug Registration Certificate" for Terbutaline Sulphate Solution for Nebulization
Filed with SSE · · 2 pages · Chinese
Release
Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on 6ix
Earlier from Zhejiang Shapuaisi Pharmaceutical
- 2025 Semi-annual Report
- Announcement on Turnaround to Profitability for the 1st Half of 2025
- Announcement on Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual Report
- Announcement on the Result of Shareholding Reduction by Shareholder through Call Auction
- Announcement on Release and Pledge of Controlling Shareholder's Shares
Later from Zhejiang Shapuaisi Pharmaceutical
- Announcement on Wholly-owned Subsidiary Obtaining Notice of Approval for Drug Clinical Trials for Pilocarpine HCI Ophthalmic Solution
- Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Resignation of Director and Election of Employee Representative Director
- Announcement on Postponement of Investment Projects Financed by Raised Funds
Follow Zhejiang Shapuaisi Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Shapuaisi Pharmaceutical